WebApr 19, 2024 · 2024年4月13日,由 中山大学附属第一医院李怡教授主持, 广东省人民医院谭宁教授、 宁波市第一医院储慧民教授和 广州医科大学附属第二医院区文超教授在POST EHRA 2024热点速递线上会议中,介绍并解读了EHRA 2024会议上最新发布的房颤(AF)领域真实世界研究 ... WebChiOTEAF 是一项国际合作、前瞻性、观察性、人群实效研究,项目由欧洲心脏病协会,中国老年保健医学研究会心血管分会 ,中华医学会老年分会 ,中华医学会心电生理和起搏 …
One‐year Follow‐up Results of the Optimal …
WebSep 22, 2024 · The ChiOTEAF is a prospective registry proceeded in 44 sites from 20 provinces in China between October 2014 and December 2024. Outcomes of interest were all-cause mortality, any thromboembolism, major bleeding, and new onset/worsening heart failure. Results. WebApr 5, 2024 · Methods and Results The ChiOTEAF (Optimal Thromboprophylaxis in Elderly Chinese Patients With Atrial Fibrillation) registry is a prospective, multicenter, nationwide study conducted from October 2014 to December 2024. The primary outcomes of interest were the composite end point of all-cause death and thromboembolic events, as well as ... durgesh tripathi
Oral anticoagulation improves survival in very elderly Chinese …
Web2 days ago · 製藥商莫德納(Moderna Inc)表示,預計2027年其呼吸道疫苗的銷售額將在80億至150億元之間。該公司在年度疫苗會議之前表示,預計將在未來幾年推出6種主要疫苗。莫德納正在測試針對呼吸道合胞病毒(RSV)、流感疫苗和處於後期研究階段的下一代新冠病毒疫 … http://www.theaterx.jp/chekhov/about.html WebJan 13, 2024 · The ChiOTEAF registry offers an opportunity to provide a better understanding of the clinical profiles and adverse outcomes of patients with AF in China and allow for comparisons with a ... cryptococcus imaging